[1]熊 雄,熊 斌,姚 烽.CYFRA21-1与BTA stat检测在膀胱癌诊断中的应用价值[J].医学信息,2020,33(22):104-106.[doi:10.3969/j.issn.1006-1959.2020.22.029]
　XIONG Xiong,XIONG Bin,YAO Feng.Application Value of CYFRA21-1 and BTA Stat in the Diagnosis of Bladder Cancer[J].Medical Information,2020,33(22):104-106.[doi:10.3969/j.issn.1006-1959.2020.22.029]
点击复制

CYFRA21-1与BTA stat检测在膀胱癌诊断中的应用价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年22期
页码:
104-106
栏目:
论著
出版日期:
2020-11-15

文章信息/Info

Title:
Application Value of CYFRA21-1 and BTA Stat in the Diagnosis of Bladder Cancer
文章编号:
1006-1959（2020）22-0104-03
作者:
熊 雄; 熊 斌; 姚 烽
（1.重庆医科大学附属第一院泌尿外科，重庆 400042；2.重庆市南川区人民医院泌尿外科，重庆 408400；3.重庆市巴南区人民医院泌尿外科，重庆 401320）
Author(s):
XIONG Xiong; XIONG Bin; YAO Feng
(1.Department of Urology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China;2.Department of Urology,Nanchuan District People’s Hospital,Chongqing 408400,China;3.Department of Urology,Banan District People’s Hospital,Chongqing 401320,China)
关键词:
膀胱癌; CYFRA21-1; BTA stat检测
Keywords:
Bladder cancer; CYFRA21-1; BTA stat test
分类号:
R737.14
DOI:
10.3969/j.issn.1006-1959.2020.22.029
文献标志码:
A
摘要:
目的 评价CYFRA21-1与BTA stat检测在膀胱癌诊断中的价值。方法 选2019年6~12月在我院经病理学检查确诊的膀胱癌患者57例为实验组，选同期泌尿系统良性疾病患者66例为良性疾病对照组，选健康体检者30名为健康对照组，比较三组血清CYFRA21-1值和尿BTA stat结果；实验组不同病理分期、临床分期的血清CYFRA21-1值和尿BTA stat结果；血清CYFRA21-1和尿BTA stat检测单独和联合诊断的敏感性、特异性、阳性预测值、阴性预测值。结果 膀胱癌组CYFRA21-1阳性率为68.40%、BTA stat检测的阳性率为85.96%，均高于泌尿系统良性疾病组（CYFRA21-1阳性率13.60%、BTA stat检测的阳性率25.76%）和健康对照组（CYFRA21-1阳性率6.70%、BTA stat检测的阳性率0）；实验组CYFRA21-1的敏感性随着膀胱癌临床分期、病理分级的升高而增加。BTA stat检测的阳性率随着临床分期的升高而增加，但在不同病理分级中无此变化；CYFRA21-1单独检测敏感性低于BTA stat检测（68.40% vs 85.96%），特异性略高于BTA stat检测（88.54% vs 82.29%）；两者做平行试验的敏感性较高，为92.98%，两者系列试验的特异性较高，为92.71%。结论 血清CYFRA21-1与尿液BTA stat检测可用于膀胱癌的诊断，两者联合检测有助于提高敏感性及特异性。
Abstract:
Objective To evaluate the value of CYFRA21-1 and BTA stat in the diagnosis of bladder cancer.Methods 57 bladder cancer patients diagnosed by pathological examination in our hospital from June 2019 to December 2019 were selected as the experimental group， 66 patients with benign urinary system diseases during the same period were selected as the control group with benign diseases， and 30 healthy subjects were selected as a healthy control group，compare the serum CYFRA21-1 values and urine BTA stat results of the three groups; the serum CYFRA21-1 values and urine BTA stat results of different pathological and clinical stages of the experimental group; the sensitivity of serum CYFRA21-1 and urine BTA stat detection alone and combined diagnosis, specificity, positive predictive value, negative predictive value.Results The positive rate of CYFRA21-1 in the bladder cancer group was 68.40%, and the positive rate of BTA stat was 85.96%, which were higher than those in the urinary system benign disease group (CYFRA21-1 positive rate was 13.60%, BTA stat positive rate was 25.76%) and healthy control group (CYFRA21-1 positive rate 6.70%, BTA stat positive rate 0); experimental group CYFRA21-1 sensitivity increased with the increase of clinical stage and pathological grade of bladder cancer. The positive rate of BTA stat test increases with the increase of clinical stage, but there was no such change in different pathological grades; the sensitivity of CYFRA21-1 alone was lower than that of BTA stat test (68.40% vs 85.96%), and the specificity was slightly higher detected by BTA stat (88.54% vs 82.29%); the sensitivity of the two parallel tests was higher, 92.98%, and the specificity of the two series of tests was higher, 92.71%. Conclusion The detection of serum CYFRA21-1 and urine BTA stat can be used for the diagnosis of bladder cancer, and the combined detection of the two helps to improve the sensitivity and specificity.

参考文献/References:

[1]Sun D,Cao M,Li H,et al.Cancer burden and trends in China:A review and comparison with Japan and South Korea[J].Chin J Cancer Res,2020,32(2):129-139.[2]Saginala K,Barsouk A,Aluru JS,et al.Epidemiology of Bladder Cancer[J].Med Sci(Basel),2020,8(1):15. [3]Alimi Q,Hascoet J,Manunta A,et al.Reliability of urinary cytology and cystoscopy for the screening and diagnosis of bladder cancer in patients with neurogenic bladder:A systematic review[J].Neurourol Urodyn,2018,37(3):916-925. [4]平秦榕,颜汝平,王剑松.膀胱癌早期诊断方法的临床价值[J].医学与哲学,2015(6):66-68,97.[5]He H,Han C,Hao L,et al.ImmunoCyt test compared to cytology in the diagnosis of bladder cancer:A meta-analysis[J].Oncol Lett,2016,12(1):83-88. [6]Pietzak EJ,Bagrodia A,Cha EK,et al.Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets[J].Eur Urol,2017,72(6):952-959. [7]Knowles MA,Hurst CD.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity[J].Nat Rev Cancer,2015,15(1):25-41. [8]Schmitz-Drager BJ,Droller M,Lokeshwar VB,et al.Molecular markers for bladder cancer screening,early diagnosis,and surveillance:the WHO/ICUD consensus[J].Urol Int,2015,94(1):1-24.[9]李林海.常见肿瘤标志物的临床应用及进展[J].中华检验医学杂志,2016,39(12):995-998.[10]Leiblich A.Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer[J].Curr Urol Rep,2017,18(12):100.[11]汪佩文,巫协宁.CYFRA21-1检测在良恶性疾病中的变化和意义[J].中华消化杂志,2017,37(11):790-792.[12]朱晓博,孔朝辉,范小玲,等.血清CYFRA21-1与浸润性膀胱尿路上皮细胞癌预后的关系[J].山东医药,2016(1):42-44.[13]Lee J,Park HL,Jeong CW,et al.CYFRA 21-1 in Lymph Node Fine Needle Aspiration Washout Improves Diagnostic Accuracy for Metastatic Lymph Nodes of Differentiated Thyroid Cancer[J].Cancers(Basel),2019,11(4):487.[14]Chen F,Li J,Qi X,et al.Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease[J].J Cancer Res Ther,2018,14(Supplement):S400-S404. [15]陈健康,彭道荣,陈慧昱,等.尿液膀胱肿瘤抗原水平检测在膀胱癌诊断中的意义[J].现代检验医学杂志,2019,34(6):135-137.[16]Chou R,Gore JL,Buckley D,et al.Urinary Biomarkers for Diagnosis of Bladder Cancer:A Systematic Review and Meta-analysis[J].Ann Intern Med,2015,163(12):922-931.[17]薛玉泉,王振龙,张亚平,等.尿膀胱肿瘤抗原在膀胱癌诊断中的临床价值及相关性分析[J].癌症进展,2019,17(1):45-48.

相似文献/References:

[1]尤 静.肺癌患者外周血CEA、NSE、CYFRA21-1联合检测的意义[J].医学信息,2018,31(06):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
　YOU Jing.Clinical Significance of Combined Detection of CEA,NSE,CYFRA21-1 in Peripheral Blood of Patients with Lung Cancer[J].Medical Information,2018,31(22):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
[2]幸世玉.经尿道电切术联合吉西他滨灌注治疗膀胱癌的临床效果分析[J].医学信息,2018,31(20):91.[doi:10.3969/j.issn.1006-1959.2018.20.026]
　XING Shi-yu.Clinical Analysis of Transurethral Resection Combined with Gemcitabine Perfusion in the Treatment of Bladder Cancer[J].Medical Information,2018,31(22):91.[doi:10.3969/j.issn.1006-1959.2018.20.026]
[3]熊波波,张劲松,王海峰,等.miRNAs与泌尿系肿瘤关系的研究进展[J].医学信息,2019,32(05):35.[doi:10.3969/j.issn.1006-1959.2019.04.013]
　XIONG Bo-bo,ZHANG Jin-song,WANG Hai-feng,et al.Research Progress on the Relationship between miRNAs and Urinary Tumors[J].Medical Information,2019,32(22):35.[doi:10.3969/j.issn.1006-1959.2019.04.013]
[4]杜国望,陈 昊,苗岳松,等.保留膀胱综合疗法治疗肌层浸润性膀胱癌的效果[J].医学信息,2020,33(06):122.[doi:10.3969/j.issn.1006-1959.2020.06.038]
　DU Guo-wang,CHEN Hao,MIAO Yue-song,et al.Effect of Bladder-preserving Comprehensive Therapy on Muscular Invasive Bladder Cancer[J].Medical Information,2020,33(22):122.[doi:10.3969/j.issn.1006-1959.2020.06.038]
[5]张晓伟,陈 明,田谋利,等.术中体位变化和气腹对机器人辅助腹腔镜根治性膀胱切除患者眼压的影响[J].医学信息,2020,33(14):113.[doi:10.3969/j.issn.1006-1959.2020.14.034]
　ZHANG Xiao-wei,CHEN Ming,TIAN Mou-li,et al.Effects of Intraoperative Posture Changes and Pneumoperitoneum on Intraocular Pressure in Patients with Robot-assisted Laparoscopic Radical Cystectomy[J].Medical Information,2020,33(22):113.[doi:10.3969/j.issn.1006-1959.2020.14.034]
[6]孙祖刚,王咸钟,谢习颂,等.慢性炎症分子基础及信号通路在膀胱癌中的作用[J].医学信息,2020,33(19):31.[doi:10.3969/j.issn.1006-1959.2020.19.010]
　SUN Zu-gang,WANG Xian-zhong,XIE Xi-song,et al.The Molecular Basis of Chronic Inflammation and the Role of Signal Pathways in Bladder Cancer[J].Medical Information,2020,33(22):31.[doi:10.3969/j.issn.1006-1959.2020.19.010]
[7]郝保良.等离子针状电极剜切治疗非肌层浸润性膀胱癌的效果[J].医学信息,2021,34(04):148.[doi:10.3969/j.issn.1006-1959.2021.04.040]
　HAO Bao-liang.Effect Plasma Needle Electrode Enucleation for Non-muscular Invasive Carcinoma of Urinary Bladder[J].Medical Information,2021,34(22):148.[doi:10.3969/j.issn.1006-1959.2021.04.040]
[8]苗岳松,刘 杰,刘 昕,等.循环肿瘤细胞在膀胱癌诊疗中的应用价值[J].医学信息,2021,34(08):72.[doi:10.3969/j.issn.1006-1959.2021.08.019]
　MIAO Yue-song,LIU Jie,LIU Xin,et al.The Application Value of Circulating Tumor Cells in the Diagnosis and Treatment of Bladder Cancer[J].Medical Information,2021,34(22):72.[doi:10.3969/j.issn.1006-1959.2021.08.019]
[9]刘 坤,陈德春.基于生信学方法分析GSDM基因家族在膀胱癌的表达及临床意义[J].医学信息,2022,35(10):14.[doi:10.3969/j.issn.1006-1959.2022.10.003]
　LIU Kun,CHEN De-chun.Expression and Clinical Significance of GSDM Gene Family in Bladder Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(22):14.[doi:10.3969/j.issn.1006-1959.2022.10.003]
[10]任默涵,于东海,吴 迪.MTHFD2基因在膀胱癌中的表达、功能富集及信号通路的生物信息学分析[J].医学信息,2022,35(24):18.[doi:10.3969/j.issn.1006-1959.2022.24.004]
　REN Mo-han,YU Dong-hai,WU Di.Expression, Functional Enrichment and Bioinformatics Analysis of MTHFD2 Gene in Bladder Cancer[J].Medical Information,2022,35(22):18.[doi:10.3969/j.issn.1006-1959.2022.24.004]

更新日期/Last Update: 1900-01-01